PubMed Health⌕ Search

Biomedical subjects

Y Tsukano

Publications and source records attributed to Y Tsukano.

7 recordsLinked to original sources
PubMed1982

Multivariate analysis using a linear discriminant function for predicting the prognosis of congestive heart failure.

Some of cases of congestive heart failure (CHF) are intractable or refractory and respond poorly to conventional treatment. We have examined factors which may influence the clinical course and prognosis. The subjects were 114 hospitalized patients with CHF. Of these, 77 had a good response to treatment and were classified as the curative group (Group C) while the remaining 37 who were difficult to treat, including those with poor prognosis, were designated the refractory group (Group R). Of the various clinical background factors including the findings of laboratory and other examinations, the following 8 variables made a significant contribution to differentiation between the 2 groups: 1) heart rate (X1), 2) hemoglobin content (X2), 3) serum K (X3), 4) serum total protein (X4), 5) A/G (X5), 6) BUN (X6), 7) grade of hepatomegaly (X7), and 8) number of previous CHF episodes (X8). The linear discriminant function represented by the following equation using these 8 variables showed an excellent result in differentiating the 2 groups. Y = - 9.64 - 0.0686X1 + 0.345X2 + 1.351X3 + 1.513X4 + + 1.988X5 - 0.0876X6 - 0.792X7 - 0.737X8. When Y value is over 0, Group C is judged. When Y value is under 0, group R is judged. We concluded that the discriminant equation covering these 8 factors is a useful means of predicting the prognosis in CHF and the response to treatment.

Adult↗
PubMed1982

Antihypertensive effects of the calcium antagonistic agent nifedipine.

The calcium antagonist nifedipine (Adalat) was administered to 60 patients with essential hypertension and investigations were performed on acute and chronic hypotensive effects. The following results were obtained: 1. Acute hypotensive effects: Nifedipine (20 mg) was either orally or sublingually administered. Following oral administration, significant hypotensive effect was attained 20 min after administration and the maximum hypotensive response was obtained 2-4 h after administration. In cases of sublingual administration, significant hypotensive effect was notable 5 min after administration and blood pressure reached the lowest level 2-3 h after administration. The hypotensive effects lasted for a relatively longer period and significantly lower blood pressure than the control level was observed even 3 h after administration. 2. Chronic hypotensive effects: Nifedipine (30-60 mg/d) was orally administered consecutively. Significant hypotensive effect was attained in and after the 4th week of administration. The yearly changes in the long-term administration cases over 3 years demonstrated significant hypotensive effects. The cases who did not respond to single administration of thiazides or beta-blockers exhibited significant hypotensive response by the combined use of nifedipine. 3. Change in heart rate: In the acute study, heart rate increased after nifedipine administration and lasted for several hours. In the long-term administration cases, the changes in heart rate were not significant. 4. Side effects attributable to nifedipine such as headache in 2 cases, facial flushing, palpitation, warm sensation and nausea in 1 case each were observed early after the administration but there were no cases in whom administration was discontinued due to these side effects.

Administration, Oral↗
PubMed1981

Treatment of angina pectoris patients with niludipine a new calcium antagonistic drug.

The antianginal effectivity of niludipine (Bay a 7168), a new calcium antagonistic drug, was investigated in angina pectoris patients, selected for admission to the trials by pre-determined strict criteria. Oral administration of from 60--120 mg niludipine daily for 4--8 weeks, resulted in the following: 1. Number of anginal attacks significantly reduced. 2. Nitrate consumption markedly lowered. 3. Investigating physicians assessed globally the clinical results of niludipine treatment on the basis of the reduction of the number of anginal attacks, nitrate consumption, improved physical ability and reports by the patients as to their subjective evaluation of the test drug. Niludipine was judged clinically effective in 21 out of 27 patients (77.8%). 4. Full records of ECGs, a necessary item for assessment, were obtained from 24 out of 27 patients. Ischemic ECGs were improved or normalized in 6 out of 24 patients (25%). 5. In the investigators' final overall assessment, including the evaluation of ECG changes, niludipine was rated effective for 20 out of 27 patients (74.1%). 6. Tolerance to the test drug was excellent. Only one patient complained of transient, mild nausea. After reduction of the daily dose, the patient completed the trial without any further appearance or complaints of side effects. Results suggest that niludipine is a useful antianginal drug in the management of coronary artery disease patients. Further clinical investigations with a larger number of patients should be conducted.

Aged↗
PubMed1981

Clinical study on the hypotensive effect of diltiazem hydrochloride.

Diltiazem HCl was administered p.o. at a fixed daily dose level of 180 mg to patients with essential hypertension, and the hypotensive effect of the drug was investigated. The following results were obtained: diltiazem HCl given alone exhibited a hypotensive effect on systolic pressure in 88.9% of the patients and on diastolic pressure in 66.7% of the patients. The concurrent use of diltiazem HCl with trichlormethiazide exerted a hypotensive effect on patients who were nonresponsive to diltiazem HCl alone. As regards side effects, one patient complained of gastric fullness and one of dizziness. However, the symptoms were so mild that further continuation of diltiazem HCl therapy was possible. From the results obtained, it is concluded that diltiazem HCl can effectively be used clinically as a hypotensive drug.

Adult↗
PubMed1976

A study on vectorcardiographic criteria for evaluating right ventricular hypertrophy in chronic obstructive pulmonary disease.

Vectorcardiographic analysis was mainly made on the basis of hemodynamic findings through right heart catheterization in COPD. From the results obtained in the present study, the authors proposed the following quantitative VCG criteria as a mean for clinical recognition of right ventricular overload in patients with COPD. (I) Individual parameters of the criteria are: i) The QRS loop; (a) P/A (posterior force/anterior force) greater than or equal to 2.8 (b) R/L (rightward force/leftward force) greater than or equal to 0.6 (c) P/6 (posterior force/leftward force) greater than or equal to 1.8 ii) The P loop; Ap/Pp (anterior force/posterior force) greater than or equal to 1.8 (II) Criteria i) "RVH (right ventricular hypertrophy)" should satisfy more than 3 of the above individual parameters. ii) "RVH suspected" should satisfy 1 or 2 of them. iii) "RVH negative" should not satisfy any of them. The recognition rate for RVH by the present VCG criteria was higher than the conventional ECG criteria and there was good correspondence with autopsy findings.

Adult↗